Does Dr. DANY ABOU ABDALLAH have financial conflicts of interest?

Dr. DANY ABOU ABDALLAH (MD) has received a total of $620 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $620 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. DANY ABOU ABDALLAH?

According to CMS Open Payments data, Dr. DANY ABOU ABDALLAH received funding from PULMONX CORPORATION ($415), ASTRAZENECA PHARMACEUTICALS ($46), and JAZZ PHARMACEUTICALS ($41).

Does Dr. DANY ABOU ABDALLAH receive research grants or speaking fees?

Dr. DANY ABOU ABDALLAH has received $620 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. DANY ABOU ABDALLAH

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: ZANESVILLE, OH 43701

NPI Number: 1033190178

LIFETIME INDUSTRY VALUE

$620

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABOU ABDALLAH is a verified Internal Medicine, Pulmonary Disease practitioner based in ZANESVILLE, OH.

Between 2021 and 2024, Dr. ABOU ABDALLAH had an overall industry promotional and research financial footprint of $620 as recorded in the federal CMS Open Payments database.

$620 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABOU ABDALLAH's primary funding source is PULMONX CORPORATION, which accounts for $415 (representing 66.9% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

PULMONX CORPORATION

Rank 1

$415

66.9%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$46

7.4%

JAZZ PHARMACEUTICALS

Rank 3

$41

6.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.